Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › APVO

Aptevo Therapeutics

APVO Lead: Phase 1 ★ Read the deep dive → 4 Biotech Distilled articles ↓ 37 filings & releases ↓ Cash $9.8M (Jun 30, 2026) ↓ 4 verdicts ↓
Oncology Protein

Market cap $2.2M 1.8M shares (10-Q, Aug 14, 2026) × $1.24 close Nov 6, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Mipletamig Ph2 readoutyear-end 2026Mipletamig Ph2 readout, year-end 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Technology platforms

ADAPTIR

ADAPTIR protein technology platform for rational design of monospecific and bispecific immunotherapeutic proteins targeting cancer; generates molecules that bind one or more targets with structural and functional advantages over monoclonal antibodies; used to develop clinical and preclinical oncology candidates

Targets: CD3, Nectin-4, PD-L1, CD40

ADAPTIR-FLEX

Proprietary flexible multispecific immunotherapy platform enabling adjustable construct design and addition of different therapeutic components; supports development of bispecific and trispecific candidates for solid tumors and hematologic malignancies, including Nectin-4 x PD-L1 backbone applications.

Targets: CD3, Nectin-4, PD-L1, CD40

Capital (as filed)

Cash
$9.8M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$5.5M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$9.8M cash per the update of Sep 3, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Aptevo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-16 Avoid Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline Serial-dilution microcap with an unproven CRS-sparing CD123xCD3 in a class larger players are abandoning, an evaluable-vs-ITT efficacy pitch that cannot demonstrate additive benefit without a control arm, a stalled partner-encumbered second program, and an explicit going-concern qualification.
  2. 2026-08-13 Avoid UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again $4.5M raise against ~$8M/quarter burn is a bridge to the next bridge, with new warrant overhang capping any RAINIER-driven rally while the efficacy claim remains structurally unprovable.
  3. 2026-08-15 Avoid UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank Company traded away 12-month access to its $66.8M equity lines for $4.5M gross, leaving warrant exercises as the only capital plan while cash stands at $9.8M against ~$6.7M/quarter burn.
  4. 2026-09-03 Avoid UPDATE: Aptevo Therapeutics (APVO) - Good Data, Wrong Week A 79% CR/CRi in TP53-mutant frontline AML is the strongest clinical signal yet but cannot outrun 6.4 million registered resale shares against a 1.81 million share count, with warrants struck 58% above market and the Yorkville lines locked out.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)